EGFR and non-small cell lung carcinoma: Osimertinib is now an FDA‐approved drug for patients with NSCLC relapsed to 1st generation EGFR‐TKIs due to T790M mutation and for EGFR mutation‐positive advanced NSCLC as a first‐line treatment.